Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Spirometry Stories

2011-04-19 01:00:00

TOKYO, April 19, 2011 /PRNewswire-FirstCall/ -- - Data From the Novartis Pivotal GLOW1 Study Show Once-Daily NVA237 met its Primary Endpoint, Demonstrating Superior Bronchodilation (Trough FEV[1]) Relative to Placebo (p<0.001) at 12 Weeks - NVA237 Significantly Improved Lung Function While Demonstrating a Good Safety Profile in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) - Detailed Results to be Presented at a Scientific Congress in H2...

2011-04-15 00:00:03

Nexus6 and Clement Clarke International announce a collaboration aimed at improving the use of inhaled medications. (PRWEB) April 14, 2011 Nexus6 and Clement Clarke International (CCI) today announced a collaboration aimed at improving the use of inhaled medications. The aim of inhaled medication in asthma and COPD is to enable the patient to maintain control of these conditions, but all too frequently control is not achieved despite widespread availability of effective medications. Some...

2011-04-11 07:00:00

To view the Social Media Release, click here: http://smr.newswire.ca/en/ontario-lung-association/ontario-lung-association-joins-forces-with-health-advocates TORONTO, April 11 /PRNewswire/ - Today, more than 2.4 million Ontarians are struggling to breathe.  With this number likely to grow by 50 per cent within 30 years, the Ontario Lung Association, in collaboration with more than 40 lung health stakeholders, is placing an urgent call to the Ontario government for the development...

2011-03-17 12:29:02

WHAT: Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM), according to the results of a new study sponsored and conducted in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. "Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis," will be published online March 16 in the New England Journal of...

2011-03-11 16:04:50

Monitoring blood for tiny particles released by cells lining the lungs may help clinicians diagnose emphysema in its earliest stages, according to researchers from Weill Cornell Medical College. The particles, called endothelial microparticles (EMPs), are shed during the disease process as tiny blood vessels in the lungs, called pulmonary capillaries, are injured and die. The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of...

2011-03-11 14:20:37

Researchers say the test, which measures destruction of lung air sacs, could help prevent progression of the common, and fatal, lung disease During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say a blood test that detects the early development of emphysema -- well before symptoms occur -- may someday also be offered. In the March 11 online...

2011-03-01 07:17:00

IRVINE, Calif., March 1, 2011 /PRNewswire/ -- Uptake Medical® Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced today that Scott Huennekens, President and CEO of Volcano Corporation, (Nasdaq: VOLC) has joined the company's Board of Directors. Mr. Huennekens has served as President, CEO and Director of Volcano since April 2002. He led the company from a pre-revenue start-up to its IPO in 2006 and its...

2011-02-23 15:20:00

EXTON, Pa., Feb. 23, 2011 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today the commercial launch of ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades and the company's first product launch in the U.S. ARIDOL is used to assess bronchial hyperresponsiveness in patients six years...

2011-01-20 16:31:34

Patients suffering from chronic obstructive pulmonary disease (COPD) who are on long-term oxygen therapy (LTOT) have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD patients on LTOT today face an increased risk of death from cardiovascular disease and other non-respiratory ailments. The study's results suggest physicians need to carefully monitor for these conditions and treat them to help decrease the risk of mortality in these...

2010-12-17 17:18:44

Cystic fibrosis (CF) patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug. Called denufosol, the investigational medication can be given early in the CF disease process, and may help delay the progression of lung disease in these patients, the researchers found. The findings were...